RESUMO
Maximum androgen blockade is the standard endocrine treatment for advanced prostate cancer. Interstitial lung disease in different degrees of severity, with low mortality and excellent response to treatment may appear with its use. We report a 77 years old patient with advanced prostate cancer who developed severe and progressive respiratory failure associated to bilateral pulmonary infiltrates, attributed to the direct effect of maximum androgen blockade. Despite the therapeutic efforts, the patient died. Lung pathology revealed Usual Interstitial Pneumonia.
Assuntos
Humanos , Masculino , Idoso , Doenças Pulmonares Intersticiais/induzido quimicamente , Antagonistas de Androgênios/efeitos adversos , Antinematódeos/efeitos adversos , Neoplasias da Próstata/tratamento farmacológico , Compostos de Tosil/efeitos adversos , Biópsia , Adenocarcinoma/tratamento farmacológico , Tomografia Computadorizada por Raios X , Doenças Pulmonares Intersticiais/patologia , Evolução Fatal , Progressão da Doença , Anilidas/efeitos adversos , Nitrilas/efeitos adversosRESUMO
Maximum androgen blockade is the standard endocrine treatment for advanced prostate cancer. Interstitial lung disease in different degrees of severity, with low mortality and excellent response to treatment may appear with its use. We report a 77 years old patient with advanced prostate cancer who developed severe and progressive respiratory failure associated to bilateral pulmonary infiltrates, attributed to the direct effect of maximum androgen blockade. Despite the therapeutic efforts, the patient died. Lung pathology revealed Usual Interstitial Pneumonia.
